Clinical implications of the oncometabolite succinate inSDHx-mutation carriers

被引：48

作者：

Eijkelenkamp, Karin ^{[1
]}

Osinga, Thamara E. ^{[1
]}

Links, Thera P. ^{[1
]}

van der Horst-Schrivers, Anouk N. A. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol & Metab Dis, Groningen, Netherlands

来源：

CLINICAL GENETICS | 2020年 / 97卷 / 01期

关键词：

oncometabolites; paraganglioma; pheochromocytoma; SDH mutation; succinate; MITOCHONDRIAL RESPIRATORY-CHAIN; GASTROINTESTINAL STROMAL TUMORS; MAGNETIC-RESONANCE-SPECTROSCOPY; RENAL-CELL CARCINOMA; MALIGNANT PHEOCHROMOCYTOMA; GENE-MUTATIONS; DEHYDROGENASE-B; SDHB-MUTATION; COMPLEX II; METASTATIC PHEOCHROMOCYTOMAS;

D O I：

10.1111/cge.13553

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Succinate dehydrogenase (SDH) mutations lead to the accumulation of succinate, which acts as an oncometabolite. GermlineSDHxmutations predispose to paraganglioma (PGL) and pheochromocytoma (PCC), as well as to renal cell carcinoma and gastro-intestinal stromal tumors. TheSDHxgenes were the first tumor suppressor genes discovered which encode for a mitochondrial enzyme, thereby supporting Otto Warburg's hypothesis in 1926 that a direct link existed between mitochondrial dysfunction and cancer. Accumulation of succinate is the hallmark of tumorigenesis in PGL and PCC. Succinate accumulation inhibits several alpha-ketoglutarate dioxygenases, thereby inducing the pseudohypoxia pathway and causing epigenetic changes. Moreover, SDH loss as a consequence ofSDHxmutations can lead to reprogramming of cell metabolism. Metabolomics can be used as a diagnostic tool, as succinate and other metabolites can be measured in tumor tissue, plasma and urine with different techniques. Furthermore, these pathophysiological characteristics provide insight into therapeutic targets for metastatic disease. This review provides an overview of the pathophysiology and clinical implications of oncometabolite succinate inSDHxmutations.

引用

页码：39 / 53

页数：15

共 160 条

[1] New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas [J].

Almeida Toledo, Rodrigo .

[2] Genetic testing in pheochromocytoma or functional paraganglioma [J].

Amar, L ;

Bertherat, J ;

Baudin, E ;

Ajzenberg, C ;

Bressac-de Paillerets, B ;

Chabre, O ;

Chamontin, B ;

Delemer, B ;

Giraud, S ;

Murat, A ;

Niccoli-Sire, P ;

Richard, SP ;

Rohmer, V ;

Sadoul, JL ;

Strompf, L ;

Schlumberger, M ;

Bertagna, X ;

Plouin, PF ;

Jeunemaitre, X ;

Gimenez-Roqueplo, AP .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8812-8818

[3] Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas [J].

Amar, Laurence ;

Baudin, Eric ;

Burnichon, Nelly ;

Peyrard, Severine ;

Silvera, Stephane ;

Bertherat, Jerome ;

Bertagna, Xavier ;

Schlumberger, Martin ;

Jeunemaitre, Xavier ;

Gimenez-Roqueplo, Anne-Paule ;

Plouin, Pierre-Francois .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (10) :3822-3828

[4] Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD [J].

Andrews, Katrina A. ;

Ascher, David B. ;

Pires, Douglas Eduardo Valente ;

Barnes, Daniel R. ;

Vialard, Lindsey ;

Casey, Ruth T. ;

Bradshaw, Nicola ;

Adlard, Julian ;

Aylwin, Simon ;

Brennan, Paul ;

Brewer, Carole ;

Cole, Trevor ;

Cook, Jackie A. ;

Davidson, Rosemarie ;

Donaldson, Alan ;

Fryer, Alan ;

Greenhalgh, Lynn ;

Hodgson, Shirley V. ;

Irving, Richard ;

Lalloo, Fiona ;

McConachie, Michelle ;

McConnell, Vivienne P. M. ;

Morrison, Patrick J. ;

Murday, Victoria ;

Park, Soo-Mi ;

Simpson, Helen L. ;

Snape, Katie ;

Stewart, Susan ;

Tomkins, Susan E. ;

Wallis, Yvonne ;

Izatt, Louise ;

Goudie, David ;

Lindsay, Robert S. ;

Perry, Colin G. ;

Woodward, Emma R. ;

Antoniou, Antonis C. ;

Maher, Eamonn R. .

JOURNAL OF MEDICAL GENETICS, 2018, 55 (06) :384-394

[5] Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases [J].

Archier, Aurelien ;

Varoquaux, Arthur ;

Garrigue, Philippe ;

Montava, Marion ;

Guerin, Carole ;

Gabriel, Sophie ;

Beschmout, Eva ;

Morange, Isabelle ;

Fakhry, Nicolas ;

Castinetti, Frederic ;

Sebag, Frederic ;

Barlier, Anne ;

Loundou, Anderson ;

Guillet, Benjamin ;

Pacak, Karel ;

Taieb, David .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (07) :1248-1257

[6] Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas [J].

Asai, Shiko ;

Katabami, Takuyuki ;

Tsuiki, Mika ;

Tanaka, Yasushi ;

Naruse, Mitsuhide .

HORMONES & CANCER, 2017, 8 (02) :108-118

[7] SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma [J].

Assadipour, Yasmine ;

Sadowski, Samira M. ;

Alimchandani, Meghna ;

Quezado, Martha ;

Steinberg, Seth M. ;

Nilubol, Naris ;

Patel, Dhaval ;

Prodanov, Tamara ;

Pacak, Karel ;

Kebebew, Electron .

SURGERY, 2017, 161 (01) :230-237

[8] Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma [J].

Astuti, D ;

Latif, F ;

Dallol, A ;

Dahia, PLM ;

Douglas, F ;

George, E ;

Sköldberg, F ;

Husebye, ES ;

Eng, C ;

Maher, ER .

AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (01) :49-54

[9] α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis [J].

Atlante, Sandra ;

Visintin, Alessia ;

Marini, Elisabetta ;

Savoia, Matteo ;

Dianzani, Chiara ;

Giorgis, Marta ;

Surun, Duran ;

Maione, Federica ;

Schnutgen, Frank ;

Farsetti, Antonella ;

Zeiher, Andreas M. ;

Bertinaria, Massimo ;

Giraudo, Enrico ;

Spallotta, Francesco ;

Cencioni, Chiara ;

Gaetano, Carlo .

CELL DEATH & DISEASE, 2018, 9

[10] MALIGNANT PHEOCHROMOCYTOMA - EFFECTIVE TREATMENT WITH A COMBINATION OF CYCLOPHOSPHAMIDE, VINCRISTINE, AND DACARBAZINE [J].

AVERBUCH, SD ;

STEAKLEY, CS ;

YOUNG, RC ;

GELMANN, EP ;

GOLDSTEIN, DS ;

STULL, R ;

KEISER, HR .

ANNALS OF INTERNAL MEDICINE, 1988, 109 (04) :267-273

← 1 2 3 4 5 6 7 8 9 10 →